




RealRate

# PHARMACEUTICAL 2019

Mersana Therapeutics Inc.  
Rank 263 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Mersana Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mersana Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Mersana Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 164% points.

The company's Economic Capital Ratio, given in the ranking table, is -339%, being 7.3% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	74,305
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	69,425
Liabilities, Non-Current	0
Other Assets	1,503
Other Compr. Net Income	141
Other Expenses	0
Other Liabilities	282
Other Net Income	1,398
Property and Equipment	2,694
Research and Development	59,915
Revenues	10,594
Selling, General and Administrative Expense	16,334

Output Variable	Value in 1000 USD
Assets	78,502
Liabilities	69,707
Expenses	76,249
Stockholders Equity	8,795
Net Income	-64,257
Comprehensive Net Income	-64,186
Economic Capital Ratio	-339%